Literature DB >> 20032014

c-ANCA-induced neutrophil-mediated lung injury: a model of acute Wegener's granulomatosis.

K Hattar1, S Oppermann, C Ankele, N Weissmann, R T Schermuly, R M Bohle, R Moritz, B Krögel, W Seeger, F Grimminger, U Sibelius, U Grandel.   

Abstract

Anti-neutrophil cytoplasmic antibodies (c-ANCA) targeting proteinase 3 (PR3) are implicated in the pathogenesis of Wegener's granulomatosis (WG). Fulminant disease can present as acute lung injury (ALI). In this study, a model of ALI in WG was developed using isolated rat lungs. Isolated human polymorphonuclear leukocytes (PMNs) were primed with tumour necrosis factor (TNF) to induce surface expression of PR3. Co-perfusion of TNF-primed neutrophils and monoclonal anti-PR3 antibodies induced a massive weight gain in isolated lungs. This effect was not observed when control immunoglobulin G was co-perfused with TNF-primed PMNs. The c-ANCA-induced oedema formation was paralleled by an increase in the capillary filtration coefficient as a marker of increased pulmonary endothelial permeability. In contrast, pulmonary artery pressure was not affected. In the presence of the oxygen radical scavenger superoxide dismutase and a NADPH oxidase inhibitor, c-ANCA-induced lung oedema could be prevented. Inhibition of neutrophil elastase was equally effective in preventing c-ANCA-induced lung injury. In conclusion, anti-PR3 antibodies induced neutrophil mediated, elastase- and oxygen radical-dependent ALI in the isolated lung. This experimental model supports the hypothesis of a pathogenic role for c-ANCA in WG and offers the possibility of the development of therapeutic strategies for the treatment of lung injury in fulminant WG.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032014     DOI: 10.1183/09031936.00143308

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  9 in total

Review 1.  Innate immune cells in the pathogenesis of primary systemic vasculitis.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2015-09-24       Impact factor: 2.631

Review 2.  Pathogenesis of ANCA-Associated Pulmonary Vasculitis.

Authors:  Marco A Alba; J Charles Jennette; Ronald J Falk
Journal:  Semin Respir Crit Care Med       Date:  2018-11-07       Impact factor: 3.119

Review 3.  Neutrophil migration: moving from zebrafish models to human autoimmunity.

Authors:  Miriam A Shelef; Sebastien Tauzin; Anna Huttenlocher
Journal:  Immunol Rev       Date:  2013-11       Impact factor: 12.988

4.  Real-time imaging reveals endothelium-mediated leukocyte retention in LPS-treated lung microvessels.

Authors:  Kathirvel Kandasamy; Geetaram Sahu; Kaushik Parthasarathi
Journal:  Microvasc Res       Date:  2012-02-08       Impact factor: 3.514

Review 5.  Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis.

Authors:  J Charles Jennette; Ronald J Falk; Adil H Gasim
Journal:  Curr Opin Nephrol Hypertens       Date:  2011-05       Impact factor: 2.894

Review 6.  Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis.

Authors:  J Charles Jennette; Ronald J Falk; Peiqi Hu; Hong Xiao
Journal:  Annu Rev Pathol       Date:  2013-01-24       Impact factor: 23.472

Review 7.  Neutrophils in animal models of autoimmune disease.

Authors:  Tamás Németh; Attila Mócsai; Clifford A Lowell
Journal:  Semin Immunol       Date:  2016-04-07       Impact factor: 11.130

Review 8.  Pathogenicity of Proteinase 3-Anti-Neutrophil Cytoplasmic Antibody in Granulomatosis With Polyangiitis: Implications as Biomarker and Future Therapies.

Authors:  Jérôme Granel; Brice Korkmaz; Dalila Nouar; Stefanie A I Weiss; Dieter E Jenne; Roxane Lemoine; Cyrille Hoarau
Journal:  Front Immunol       Date:  2021-02-18       Impact factor: 7.561

9.  The emerging role of neutrophils in thrombosis-the journey of TF through NETs.

Authors:  Konstantinos Kambas; Ioannis Mitroulis; Konstantinos Ritis
Journal:  Front Immunol       Date:  2012-12-18       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.